Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection

ABSTRACT During the transition from acute to chronic infection in individuals persistently infected with hepatitis C virus (HCV), cellular responses initiate within the first 6 months of primary infection and collapse thereafter, whereas humoral responses activate later during the chronic phase. Whether and how this deviation of immune responses specifically influences HCV evolution are unknown. To determine the pattern of HCV evolution during this critical period, we conducted extensive sequence analysis on annual clonal hemigenomic sequences for up to 3 years in six well-characterized subjects, using statistical methods that accounted for repeated measures. Significantly different evolutionary rates were observed in envelope versus nonenvelope genes, with an increasing rate of nonsynonymous change (dN) in envelope genes and a stable dN in nonenvelope genes (P = 0.006). The ratio of the envelope to nonenvelope nonsynonymous rate increased from 2 in year 1 to 5 in years 2 and 3. Centripetal changes (reversions toward matching of the worldwide subtype 1a consensus sequence) were frequently observed during the 3-year transition from acute infection to chronicity, even in the presence of neutralizing antibody (NAb) pressure. Remarkably, sequences of hypervariable region 1 (HVR1) remained stable for up to 21 months in the absence of NAb pressure in one subject, followed by rapid changes that were temporally associated with the detection of NAb responses, which strongly suggests that HVR1 evolution is shaped by NAb pressure. These data provide the first systematic estimates of HCV evolutionary rates in multiple genes during early infection in vivo and provide additional evidence for deterministic, rather than random, evolution of HCV.

[1]  Austin L. Hughes,et al.  Extraepitopic Compensatory Substitutions Partially Restore Fitness to Simian Immunodeficiency Virus Variants That Escape from an Immunodominant Cytotoxic-T-Lymphocyte Response , 2004, Journal of Virology.

[2]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[3]  O. Pybus,et al.  Analysis of the Evolutionary Forces in an Immunodominant CD8 Epitope in Hepatitis C Virus at a Population Level , 2008, Journal of Virology.

[4]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[5]  J. Sidney,et al.  High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection1 , 2008, The Journal of Immunology.

[6]  John Sidney,et al.  Reversion of CTL escape–variant immunodeficiency viruses in vivo , 2004, Nature Medicine.

[7]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[8]  P. Klenerman,et al.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained , 2000, European journal of immunology.

[9]  S. Ray,et al.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. , 2009, Gastroenterology.

[10]  Katrina Walsh,et al.  Rapid Viral Escape at an Immunodominant Simian-Human Immunodeficiency Virus Cytotoxic T-Lymphocyte Epitope Exacts a Dramatic Fitness Cost , 2005, Journal of Virology.

[11]  Chen Liu,et al.  An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection , 2004, Hepatology.

[12]  Gary D. Stormo,et al.  Displaying the information contents of structural RNA alignments: the structure logos , 1997, Comput. Appl. Biosci..

[13]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[14]  S. Ray,et al.  Progression of Fibrosis during Chronic Hepatitis C Is Associated with Rapid Virus Evolution , 2007, Journal of Virology.

[15]  Stuart C. Ray,et al.  Divergent and convergent evolution after a common-source outbreak of hepatitis C virus , 2005, The Journal of experimental medicine.

[16]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. P. Zhao,et al.  HIV Quasispecies and Resampling , 1996, Science.

[18]  R. Purcell,et al.  Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain , 2008, Journal of Virology.

[19]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[20]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[21]  J. McKeating,et al.  Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies , 2007, Hepatology.

[22]  J. Sidney,et al.  Cellular immune selection with hepatitis C virus persistence in humans , 2005, The Journal of experimental medicine.

[23]  David Posada,et al.  MODELTEST: testing the model of DNA substitution , 1998, Bioinform..

[24]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Wright,et al.  Acute hepatitis C , 2001, Hepatology.

[26]  C. Rice,et al.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. , 2007, Gastroenterology.

[27]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[28]  R. Lanford,et al.  Viral Persistence, Antibody to E1 and E2, and Hypervariable Region 1 Sequence Stability in Hepatitis C Virus-Inoculated Chimpanzees , 1999, Journal of Virology.

[29]  O. Laeyendecker,et al.  Hypervariable Region 1 Sequence Stability during Hepatitis C Virus Replication in Chimpanzees , 2000, Journal of Virology.

[30]  D. Vlahov,et al.  Determinants of the quantity of hepatitis C virus RNA. , 2000, The Journal of infectious diseases.

[31]  K. Reddy,et al.  Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. , 2007, Gastroenterology.

[32]  D. Vlahov,et al.  Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection , 1999, Hepatology.

[33]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[34]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[35]  R. Purcell,et al.  Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes , 1995, Seminars in liver disease.

[36]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[37]  Alan S. Perelson,et al.  The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection , 2009, The Journal of experimental medicine.

[38]  G. Lauer,et al.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C , 2005, Hepatology.

[39]  Hepatitis C: global prevalence. , 1997, Releve epidemiologique hebdomadaire.

[40]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Rice,et al.  Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity , 2009, Journal of Virology.

[42]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[43]  D. Nickle,et al.  Consensus and Ancestral State HIV Vaccines , 2003, Science.

[44]  O. Laeyendecker,et al.  Accurate Representation of the Hepatitis C Virus Quasispecies in 5.2-Kilobase Amplicons , 2004, Journal of Clinical Microbiology.

[45]  Alessandro Sette,et al.  Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection , 2004, Journal of Virology.

[46]  Todd M. Allen,et al.  Viral Sequence Evolution in Acute Hepatitis C Virus Infection , 2007, Journal of Virology.

[47]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[48]  A. Weiner,et al.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.

[49]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[50]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[51]  S. Ray,et al.  Humoral immune response in acute hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[53]  P. Klenerman,et al.  Escape from HLA-B*08-Restricted CD8 T Cells by Hepatitis C Virus Is Associated with Fitness Costs , 2008, Journal of Virology.

[54]  D. Vlahov,et al.  Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  Todd M. Allen,et al.  HIV evolution: CTL escape mutation and reversion after transmission , 2004, Nature Medicine.

[56]  C. Rice,et al.  Neutralizing antibody response during acute and chronic hepatitis C virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Todd M. Allen,et al.  CD8 Epitope Escape and Reversion in Acute HCV Infection , 2004, The Journal of experimental medicine.

[58]  Todd M. Allen,et al.  Impaired Hepatitis C Virus-Specific T Cell Responses and Recurrent Hepatitis C Virus in HIV Coinfection , 2006, PLoS medicine.

[59]  Christos J. Petropoulos,et al.  Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus , 2006, The Journal of experimental medicine.

[60]  H. Thomas,et al.  Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients , 1998, Hepatology.

[61]  J. McKeating,et al.  Hepatitis C virus entry and neutralization. , 2008, Clinics in liver disease.

[62]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.